Cargando…

Quantitative determination, by real-time reverse transcription polymerase chain reaction, of aromatase mRNA in invasive ductal carcinoma of the breast

BACKGROUND: Estrogen is a mitogenic factor that is implicated in the genesis and progression of breast cancer via its binding to estrogen receptor (ER)-α. Synthesis of estrogen in situ is believed to be catalyzed mainly by aromatase. Previous studies comparing the relative contributions from tumor c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Zhenhuan, Yamashita, Hiroko, Toyama, Tatsuya, Omoto, Yoko, Sugiura, Hiroshi, Hara, Yasuo, Wu, Xueqing, Kobayashi, Shunzo, Iwase, Hirotaka
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2003
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC314416/ https://www.ncbi.nlm.nih.gov/pubmed/14580261

Ejemplares similares

Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer
por: Yamashita, Hiroko, et al.
Publicado: (2004)

p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer
por: Yamashita, Hiroko, et al.
Publicado: (2006)

Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion
por: Okumura, Yasuhiro, et al.
Publicado: (2008)

Phosphorylation of estrogen receptor α serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer
por: Yamashita, Hiroko, et al.
Publicado: (2005)

Reproductive history and breast cancer risk
por: Kobayashi, Shunzo, et al.
Publicado: (2012)

Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers
por: Toyama, Tatsuya, et al.
Publicado: (2008)

Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer
por: Yamamoto, Yutaka, et al.
Publicado: (2013)

Estrogen Receptor, c‐erbB‐2 and nm23/NDP Kinase Expression in the Intraductal and Invasive Components of Human Breast Cancers
por: Kobayashi, Shunzo, et al.
Publicado: (1992)

Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients
por: Toyama, Tatsuya, et al.
Publicado: (2007)

Analysis of Oncogenes and Tumor Suppressor Genes in Human Breast Cancer
por: Yamashita, Hiroko, et al.
Publicado: (1993)

Clinical significance of estrogen receptor β in breast and prostate cancer from biological aspects
por: Omoto, Yoko, et al.
Publicado: (2015)

Loss of heterozygosity at the ATBF1-A locus located in the 16q22 minimal region in breast cancer
por: Kai, Kazuharu, et al.
Publicado: (2008)

PTIP Associated protein 1, PA1, Is an Independent Prognostic Factor for Lymphnode Negative Breast Cancer
por: Takeshita, Takashi, et al.
Publicado: (2013)

Production of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Human Breast Carcinomas
por: Iwata, Hiroji, et al.
Publicado: (1996)

DNA methylation analysis at distal and proximal promoter regions of the oestrogen receptor gene in breast cancers
por: Iwase, H, et al.
Publicado: (1999)

Genetic and environmental factors and serum hormones, and risk of estrogen receptor-positive breast cancer in pre- and postmenopausal Japanese women
por: Guo, Jiazhi, et al.
Publicado: (2017)

Phylogenetic analysis of combined lobular and ductal carcinoma of the breast
por: Kobayashi, Hiroko, et al.
Publicado: (2021)

Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study
por: Iwase, H, et al.
Publicado: (2013)

A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer
por: Shiba, Eiichi, et al.
Publicado: (2015)

Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial
por: Ohashi, Yasuo, et al.
Publicado: (2017)

Myoepithelial Carcinoma of the Breast Treated with Surgery and Chemotherapy
por: Endo, Yumi, et al.
Publicado: (2013)

Collaborative care intervention for the perceived care needs of women with breast cancer undergoing adjuvant therapy after surgery: a feasibility study
por: Momino, Kanae, et al.
Publicado: (2017)

Ratio of Expression of p16(INK4a) to p14(ARF) Correlates with the Progression of Non‐small Cell Lung Cancer
por: Moriyama, Satoru, et al.
Publicado: (2002)

Primer‐dependent Amplification of mdr1 mRNA by Polymerase Chain Reaction
por: Sugawara, Isamu, et al.
Publicado: (1992)

Prognostic Significance of Occult Bone Marrow Micrometastases of Breast Cancer Detected by Quantitative Polymerase Chain Reaction for Cytokeratin 19 mRNA
por: Ikeda, Noriko, et al.
Publicado: (2000)

Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment
por: Takagi, K, et al.
Publicado: (2013)

Prognostic role of PIK3CA mutations of cell‐free DNA in early‐stage triple negative breast cancer
por: Takeshita, Takashi, et al.
Publicado: (2015)

Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients
por: Takeshita, Takashi, et al.
Publicado: (2016)

Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients
por: Takeshita, Takashi, et al.
Publicado: (2017)

Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients
por: Takeshita, Takashi, et al.
Publicado: (2017)

Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients
por: Takeshita, Takashi, et al.
Publicado: (2017)

POLYMERASE CHAIN REACTION
por: Wages, J.M.
Publicado: (2005)

Analysis of normal and osteoarthritic canine cartilage mRNA expression by quantitative polymerase chain reaction
por: Clements, Dylan N, et al.
Publicado: (2006)

Long-Term Effect of Aromatase Inhibition in Aromatase Excess Syndrome
por: Binder, Gerhard, et al.
Publicado: (2021)

Quantitative Analysis of Long-Form Aromatase mRNA in the Male and Female Rat Brain
por: Tabatadze, Nino, et al.
Publicado: (2014)

Immunohistochemical analysis in ethinylestradiol-treated breast cancers after prior long-term estrogen-deprivation therapy
por: Omoto, Yoko, et al.
Publicado: (2015)

Prescription Surveillance and Polymerase Chain Reaction Testing to Identify Pathogens during Outbreaks of Infection
por: Sugiura, Hiroaki, et al.
Publicado: (2013)

Characterising an aromatase inhibitor resistant breast cancer cell line
por: Harris, E, et al.
Publicado: (2012)

Sequencing of aromatase inhibitors
por: Bertelli, G
Publicado: (2005)

Modulation of Aromatase by Phytoestrogens
por: Lephart, Edwin D.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_m16r438s2b1gep4gs14mvp4lse